BCL2 inhibition: back to the future!

In this issue of Blood, Liu and colleagues report the preliminary characterization of a new BCL2-specific inhibitor (BCL2i), sonrotoclax, which not only binds with higher affinity to BCL2 than the first-in-class BCL2i venetoclax, but also induces apoptosis in models bearing venetoclax-induced BCL2 mutations.1 These important data suggest that sonrotoclax may find clinical applications in BCL2-dependent malignancies. [Opening paragraph]